Abbott’s HeartMate 3 Heart Pump Receives the US FDA’s Approval for Patients to Avoid Open Heart Surgery

 Abbott’s HeartMate 3 Heart Pump Receives the US FDA’s Approval for Patients to Avoid Open Heart Surgery

Abbott Reports Results of High Sensitive Troponin-I Blood Test for Risk Assessment of Heart Diseases

Shots:

  • The approval is based on two studies: the ELEVATE and LAT Feasibility study assessing HeartMate 3 Heart Pump and resulted that bleeding (requiring surgery), infection and arrhythmias is higher in patients with an open heart rather than group implanted
  • The MOMENTUM 3 clinical trial has also demonstrated successful implants and offering survival rates with its design and size as compared to open-heart surgery
  • The HeartMate 3 Heart Pump can be implanted with small incision in the chest via lateral thoracotomy leading to less bleeding with shorter recovery time for patients and is alternative for patients receiving HeartMate 3 LVAD, a small implantable mechanical circulatory support device for heart failures

Click here to read full press release/ article | Ref: Abbott | Image: Behance

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post